CFDE Data Portal | Search RANBP9

	Label	Description
	RANBP9 Gene (Entity type)	ENSG00000010017 - RAN binding protein 9
	RANBP9 associations Collection (Entity type)	Associations for RANBP9_associations
	RANBP9 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE128730 3 V 5 NERATINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 3 V 5 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 ivermectin prostate gland 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

RANBP9

ENSG00000010017 - RAN binding protein 9

RANBP9 associations

Associations for RANBP9_associations

RANBP9 associations.tsv

A file from IDG as part of the Harmonizome project

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE128730 3 V 5 NERATINIB HUMAN UP

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

A Gene Set from LINCS

GSE199107 tryptophan 6 v 7 human up

A Gene Set from LINCS

GSE135350 3 V 5 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP

A Gene Set from LINCS

GSE169356 ivermectin prostate gland 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.